Cogent Biosciences (NASDAQ:COGT) Issues Earnings Results, Beats Expectations By $0.50 EPS

Posted by Trevor Kearing on Feb 25th, 2025

Cogent Biosciences (NASDAQ:COGT – Get Free Report) posted its quarterly earnings data on Tuesday. The technology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.50, Zacks reports.

Cogent Biosciences Stock Down 11.3 %

Shares of NASDAQ COGT opened at $7.10 on Tuesday. The firm has a market cap of $784.28 million, a PE ratio of -2.95 and a beta of 1.77. The company’s fifty day simple moving average is $8.23 and its 200 day simple moving average is $9.59. Cogent Biosciences has a 12-month low of $5.73 and a 12-month high of $12.61.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wedbush reiterated a “neutral” rating and issued a $11.00 price target on shares of Cogent Biosciences in a research note on Monday, January 13th. JPMorgan Chase & Co. boosted their target price on Cogent Biosciences from $19.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Needham & Company LLC downgraded shares of Cogent Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, HC Wainwright cut their target price on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Cogent Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.

Read Our Latest Stock Analysis on COGT

About Cogent Biosciences

(Get Free Report)

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.